Lizhi Chen | Carter Ledyard & Milburn LLP

Lizhi Chen represents domestic and international clients in capital market matters and M&A transactions, including U.S. IPOs, SPAC and de-SPAC transactions, shelf offerings, private placement, going private transactions, public M&A, and securities compliance matters. Lizhi has extensive experience drafting prospectus, SEC filings, purchase agreements, due diligence reports.

Before joining Carter Ledyard, Lizhi spent three years at a leading international law firm, where she specialized in U.S. and international capital markets, cross-border M&A transactions, and general corporate matters.

While attending Columbia Law School, Lizhi was a Staff Editor for the Columbia Business Law Review. Prior to Columbia, Lizhi earned her LL.M and LL.B from China University of Political Science and Law.

Lizhi currently serves as an arbitrator and mediator for the Guangzhou Arbitration Commission in Canton, China and the China International Mediation and Arbitration Institute (CIMAI) in Hong Kong, China. She also holds the position of Secretary-General at CIMAI.

Lizhi is a native Mandarin and Cantonese speaker.

Lizhi's prior experience includes:

Capital Markets

Represented Pinnacle Food Group Limited (NASDAQ: PFAI), a Canadian provider of smart farming solutions specializing in vertical and hydroponic farming, in its US$7.2 million initial public offering and listing on the NASDAQ.
Represented a Shanghai IT consulting company in its confidential filing for a US IPO.
Represented the underwriters of a logistics company in its IPO on the NASDAQ.
Represented a leading Chinese home services platform company in its confidential filing for a US IPO.
Represented a leading Chinese convenience store chain company in its pre-IPO financing and filing for a US IPO.
Represented BingEx Limited (NASDAQ: FLX), a leading on-demand dedicated courier service provider in China, in its US$66 million initial public offering of American depositary shares and listing on the NASDAQ.
Represented the underwriters of the US$200 million SPAC offering by Generation Asia I Acquisition Limited (NYSE: GAQ), a SPAC sponsor focusing on the TMT, business services, and consumer sectors, on the NYSE.
Represented KE Holdings Inc. (NYSE: BEKE, HKEX: 2423), a leading TMT company engaged in housing transactions and related services, in its dual-primary listing by way of introduction on the HKEX.
Represented Zhihu Inc. (NYSE: ZH, HKEX: 2390), a leading TMT online content company, in its US$106 million dual-primary listing of Class A ordinary shares on the HKEX.
Represented YSB Inc. (HKEX: 9885), a leading pharmaceuticals sales platform, in its HK$316 million IPO on the HKEX.
Represented the underwriters of the US$442 million secondary listing of shares in Baozun Inc. (HKEX: 9991), a leading provider of supply chain solutions and e-commerce services, on the HKEX.

Mergers and Acquisitions

Represented Prenetics Group Limited (NASDAQ: PRE), a genetic and diagnostic health testing company based in HK and UK, in its de-SPAC merger with Artisan Acquisition Corp., at an equity value of US$1.7 billion.
Represented ECARX Holdings, Inc. (NASDAQ: PRE), a global automotive technology provider, in its de-SPAC merger with COVA Acquisition Corp. at an enterprise value of US$3.8 billion.
Represented Camelot Information Systems, a provider of IT services in China, in its sale of an 80% stake to Kingsoft Cloud (NASDAQ: KC), a cloud service company.
Represented a US-listed pharmaceutical company in its going-private acquisition by an investor consortium.

SEC Filing and Compliance

Represented many US-listed life science, healthcare, technology, and vehicle companies, in managing SEC filings and general compliance matters.

Investigation and Dispute Resolution

Represented a US-listed multinational pharmaceutical and biotechnology corporation in several FCPA compliance matters and internal investigations.
Represented a US-listed fintech company in a securities class action.
Represented a pharmaceutical investment company in an intellectual property case.